ArticleSensors (Basel, Switzerland)2023
Clinical Evaluation in Parkinson's Disease: Is the Golden Standard Shiny Enough?
Article in Sensors (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Real-world gait study of Parkinson's disease using wearable sensors: a systematic review.Journal of neuroengineering and rehabilitation · 2026Pooled it
- Weekly Variability of an Objective Bradykinesia Score in Parkinson's Disease-An Observational Longitudinal Study.Journal of clinical medicine · 2026Article
- AI-Enabled Wearables for Motor Function Assessment and Rehabilitation in Parkinson Disease: Scoping Review.Journal of medical Internet research · 2026Review
- Association between wrist-worn actigraphy and the MDS-UPDRS Parkinson's disease rating scale through machine learning: an exploratory study.Frontiers in digital health · 2026Article
- User Experiences of Limb-Worn Wearable Devices for Monitoring Parkinson Disease Motor Function and Blood Pressure: Usability Study.JMIR formative research · 2025Article
- Interpretable Machine Learning for Cross-Cohort Prediction of Motor Fluctuations in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Assessing Eligibility for Apomorphine Therapy in Parkinson's Disease: The Telemonitoring Potential.Movement disorders clinical practice · 2025Article
- Review
- Perspectives on digital health and advanced treatment referral in Parkinson's care among Danish neurologists: a mixed methods study.Frontiers in neurology · 2025Article
- Evaluation of compliance and accuracy in Parkinson's disease motor symptom tracking: a comparative study of digital and traditional paper diaries using a smartphone application (MyParkinson's).Frontiers in neurology · 2025Article
- [Commercial devices for monitoring symptoms in Parkinson's disease: benefits, limitations and trends].Revista de neurologia · 2024Review
- Assessing the clinical utility of inertial sensors for home monitoring in Parkinson's disease: a comprehensive review.NPJ Parkinson's disease · 2024Article
- Unveiling the Unpredictable in Parkinson's Disease: Sensor-Based Monitoring of Dyskinesias and Freezing of Gait in Daily Life.Bioengineering (Basel, Switzerland) · 2024Article
- Commercial symptom monitoring devices in Parkinson's disease: benefits, limitations, and trends.Frontiers in neurology · 2024Review
- Editorial: Remote monitoring technologies in neurodegenerative movement disorders.Frontiers in neurology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) has become the second most common neurodegenerative condition following Alzheimer's disease (AD), exhibiting high prevalence and incident rates. Current care strategies for PD patients include brief appointments, which are sparsely allocated, at outpatient clinics, where, in the best case scenario, expert neurologists evaluate disease progression using established rating scales and patient-reported questionnaires, which have interpretability issues and are subject to recall bias. In this context, artificial-intelligence-driven telehealth solutions, such as wearable devices, have the potential to improve patient care and support physicians to manage PD more effectively by monitoring patients in their familiar environment in an objective manner. In this study, we evaluate the validity of in-office clinical assessment using the MDS-UPDRS rating scale compared to home monitoring. Elaborating the results for 20 patients with Parkinson's disease, we observed moderate to strong correlations for most symptoms (bradykinesia, rest tremor, gait impairment, and freezing of gait), as well as for fluctuating conditions (dyskinesia and OFF). In addition, we identified for the first time the existence of an index capable of remotely measuring patients' quality of life. In summary, an in-office examination is only partially representative of most PD symptoms and cannot accurately capture daytime fluctuations and patients' quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.